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Introduction. More than 30 years ago, we discussed the 
prospects of TRIZ application (the theory of inventive 
problem solving in medical drug development with 
Genrich Altshuller, who is creator of the TRIZ. TRIZ is a 
problem-solving, analysis and forecasting philosophy of 
thinking derived from the study of patterns of invention 
and theory evolution. While TRIZ has been used widely in 
different fields of human life, mainly fields of technology, 
there is one field where it has not been utilized, 
pharmaceutical and medical fields.  
This is an area which affects almost every family, 
and each and every one of us. Namely, the development of 
new effective and harmless drugs. Our company first in the 
world focuses on the application of TRIZ in drug 
development to create synergistic combinations of existing 
drugs and discover their unique function, as well as, 
designing new drugs with non-standard properties. As a 
result, based on principles of TRIZ and computerized 
mathematical modeling, we have created a line of new 
dynamic, quasi-living, self-organizing medical drugs.  
According to TRIZ there are several main laws of   system 
development: Increase the degree of ideality; Irregular 
evolution of system parts & coordination; Increase the 
degree of system dynamics; Increase of manageability of 
the system; Transition of a system to a super system. In 
order to improve their performance, rigid systems should 
become more dynamic: evolve to more flexible and rapidly 
changing structures, adaptable to changes of working 
conditions and requirements of the environment. We have 
applied its principles for many years to solve various 
problems.  As a result, in late 80’s we came up with the 
idea of “self-organizing” dynamic drugs. Drugs dynamic 
features would allow them the possibility of adapting to 
each specific medical disease- the first goal was to target 
anti-cancer and antiviral by liposomal drugs. One aspect of 
approach was the idea of a plurality of components (the 
combinatorial principle). We made analogy with a set of 
master keys for different locks (a universal combinatorial 
antiviral drug) would be preferred over the common 
approach, one key for one lock (one drug for one receptor). 
We had worked persistently and in 1997, the first 
model of such a structure based on oligopeptides of horse 
albumin was revealed. We named this project and called 
Albuvir (combined from the word Albumin and the word 
virus) and applied in veterinary medicine, where viral 
infections represent more than 95% of all pathologies. In 
2000 an application was filed for the first modification of 
this drug. 
Subsequently, for the production and sale of this 
product, registration certificates of the State Committees in 
Veterinary Medicine of Eastern European countries were 
obtained.  
In 2010, we signed a license agreement to transfer 
of limited rights in the field of veterinary medicine for the 
production and sale of Albuvir in Eastern Europe. The drug 
was produced commercially and was successfully used to 
cure hundreds of thousands of chickens, rabbits, sheeps, 
cows, pigs, pigeons, fish (industrial - sturgeon), cats, dogs, 
geese, ducks, and other types of farm birds and animals. 
Over the years, we have made significant progress 
to improve Albuvir effectiveness. Our new, much stronger 
modifications, has shown that it works successfully on 
multiple different viral infections and has a minimum of 
side effects. Since the effectiveness of Albuvir increased, 
we even managed to reduce the therapeutic dose of the drug 
and increase the bioavailability and speed of the first 
manifestations of the pharmacological effect. In order to 
check effectiveness of the drug, we study influence of the 
drug on the reproduction and apoptosis of cells latently 
infected with the Epstein-Barr virus in vitro. 
The Epstein-Barr virus (EBV) is a DNA-
containing herpesvirus that has the ability to persist for life 
in the host [1]. It was previously thought to be a safe virus 
that can sometimes cause mononucleosis in humans [2]. 
Later evidence emerged that EBV has oncogenic 
properties. Clear correlations were established between 
EBV and a number of tumors, in particular - 
nasopharyngeal adenocarcinoma, lymphogranulomatosis, 
gastric cancer, esophageal cancer [3]. Recently, there are 
more links and articles related to triggering role of this 
virus in the development of atherosclerosis and in the 
development of chronic lifelong immunodeficiency [4]. 
The latter is associated with a high lymphotropicity of 
EBV, especially towards B-lymphocytes and plasma cells. 
With latent EBV infection, the production of high avidity 
immunoglobulins for almost all pathogens is significantly 
reduced. This causes both a hyperfunction of the immune 
system in the form of allergies such as asthma, skin 
allergies and autoimmune pathologies such as lupus and 
rheumatoid arthritis, with obvious background of a PCR 
test positive for EBV (more than 105 DNA copies / ml) [5]. 
Recently, more and more scientists consider EBV to be the 
cause of the development of multiple autoimmune disease, 
incl. allergic pathologies. EBV also contributes to severe 
inflammatory processes of the central and peripheral 
nervous systems, causing meningoencephalitis, meningitis, 
neuritis and arachnoencephalitis [6]. Therefore, the 
development of drugs that would contribute to the 
elimination of the EBV pathogen both in the phase of 
active reproduction and in the latent phase is an urgent task 
of modern virology. Recently, many novel therapeutics 
have been studied to eliminate latently affected cells 
through apoptosis, through the activation of the expression 
of latent EBV proteins in combination with standard drugs. 
[7]. This is a group of drugs - activators of histone 
decetylase [8]. One of the most interesting drugs in this 
novel group is the fairly widespread drug valproic acid and 
its derivatives. The valproates have been shown, activation 
and transfer of the latent form of EBV into the active phase. 
In the active phase, this virus is quite well treated with 
acyclovir derivatives (ganciclovir). The combination of 
valproic acid with ganciclovir and anticancer agents 
showed a statistically significant increase in the 
effectiveness of treatment of certain types of cancer in the 
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clinic [9]. In our study, we studied the effect of the dynamic 
antiviral agent Albuvir on the latent and active phase of 
EBV viral reproduction. Albuvir is a modified oligopeptide 
based on the nuclear localization signals of importins. Its 
use not only suppresses the reproduction of the virus, but 
is also able to stimulate the apoptosis of latently infected 
cells [10]. It is also able to adapt to viruses and cells of every 
organism, having the ability to self-assembly and self-
organization on signal peptides of nuclear localization and 
nucleolar polyribosomes. Drug development is one of the 
most important research areas, which affects each one of 
us. However, nobody has used TRIZ as a philosophy of 
solving problems in pharmaceutical research and 
development. The application of the principles of TRIZ in 
this arena opens up broad prospects in the creation of new 
classes of drugs that can independently adapt to the 
patient's body.  
The combination of contradictions, laws of 
development systems, algorithms, Su-field analysis, TRIZ 
principles, deep fundamentals of pharmaceutical industry 
and pharmacology, modern computer mathematical 
modeling, in the solution of each of the tasks at once, 
allows us to achieve extraordinary results and obtain 
significantly more effective novel drugs. For the first time 
in the world we have developed dynamic self-organizing, 
quasi live drugs, based on the principles of TRIZ and 
computerized mathematical modeling [11,12,13]. 
  These drugs capable of adapting independently 
both to the human body and to molecular targets, including 
viruses, cancer cells and microorganisms. Applying TRIZ 
and mathematical modeling in pharmaceutical industry, 
produces novel and future R&D trends. This increased the 
yield of novel dynamic drugs [14]. The dynamic drugs can 
overcome many problems from resistance to the slippage 
effect, to eliminate the side effects of drugs [15].This will 
save millions of lives. Despite changes in the concept of 
drug development: from banal screening (out of thousands 
of synthesized compounds, only one showed biological 
activity) to those obtained as a result of molecular 
modeling (another name is drug-design).  
Albuvir is composed of a mixture of acylated 
peptides. It effectively inhibits the process of nuclear 
importation of viral polynucleotides from those viruses that 
depend on the cell nucleus (FLU, Herpes Viruses, 
HIV/AIDS) [16].  Currently Albuvir is widely used as a 
veterinary drug on the market for the treatment of animals 
infected with viruses and for the prevention of animal 
mortality from excessive replication of vaccine viruses 
during vaccination [17,18]. The mechanism of action of 
Albuvir is based on the temporary inhibition of nuclear 
import peptides (alpha- and beta-importins) [19]. 
Carboxylated Albuvir peptides bind to the nuclear import 
peptide signal, and block both viral genome penetration 
into the cell nucleus and the release of viral particles of 
DNA from the nucleus. At the same time, on the target 
(imported), the active inhibitor self-assembles from 
various inactive Albuvir peptides. Albuvir 
pharmacological indicators: LD50 = 2880 mg / kg, ED50 = 
25 mg / kg, Ti = 115.2, T1/2 = 29 min, application method: 
per oral. Albuvir has antiviral activity for Influenza virus, 
Herpes viruses Types 1 and 2, Human Cytomegalovirus, 
Herpes Zoster virus, Epstein-Barr virus, Coronavirus. 
What is the TRIZ contradiction? On one side – drugs are 
static substances and cannot effectively use one drug 
treatment of multiple viral infections, on the other, 
different viruses have many different signals of importins 
and for treatment of those viral infections we need many 
different drugs (one virus– one drug). It means our one 
drug must be “smart”, substitute many drugs and self-
adjust to multiple viruses. This contradiction was resolved 
by our company using the principles of TRIZ.  
The idea of creating Albuvir was based on 
principles of TRIZ: fragmentation (to divide an object into 
independent fragments — fragmentation of whole proteins 
into oligopeptides with replacement of their charge); the 
principle of dynamism: 
a) the characteristics of the object should be 
changed so as to be optimal at each stage - for different 
viruses and different sequences of nuclear import peptide 
signals, a different sequence of inhibitor from a mixture of 
Albuvir peptides;  
b) to divide the object into parts capable of 
moving relatively to each other - fragmentation of proteins 
to Albuvir oligopeptides); the principle of copying (instead 
of an inaccessible, complicated, expensive, inconvenient or 
fragile object to use its simplified and cheap copies - 
instead of synthesizing a highly specific and expensive 
non-peptide inhibitor of nuclear import signals, use a 
mixture of oligopeptides with different sequences from 
available raw materials);  
c) the principle of homogeneity (objects 
interacting with this object should be made from the same 
material or close to it in properties - instead of synthesizing 
complex highly specific xenobiotic, use fully biodegrading 
peptides from natural sources, but with preliminary 
replacement from charges with opposite ones); the 
principle of rejection and regeneration of parts (having 
fulfilled its purpose or become an unnecessary part of an 
object must be discarded (dissolved, evaporated, etc.) or 
modified directly during the work - complete 
biodegradation of “spent” and excessive concentrations of 
Albuvir peptides without toxic metabolites; 
d) the principle of dissociation-association 
(“Dissociation-association” is stronger than the 
“separation-association”. It allows the substance to split 
apart when necessary, and when it is necessary to turn into 
one substance again — the Albuvir complementary 
peptides are associated with nuclear import peptides);  
e) the principle of self-organization (self-
assembling of an active substance from inactive precursors 
- out of thousands of synthesized Albuvir peptides, only a 
small number of high-affinity fragments will be associated 
with the signal peptides of beta-importins, and for each 
virus these will be their peptides) [20,21] 
Thus, the task of this work was to study the ability 
of Albuvir to inhibit EBV reproduction and induce 
apoptosis of latently infected cells in the culture. 
 
Materials and methods.  
Cell culture. The inhibitory effect of Albuvir on EBV was 
studied in the following cell cultures: Raji - cell culture of 
the B-phenotype of Burkitt's lymphoma (human 
lymphocytes transformed by EBV, which have 63 copies 
of the viral genome in their genome, and produce only 
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individual early antigens, and not whole viral particles). 
Namalwa is a B-phenotype cell culture from Burkitt's 
lymphoma that lacks the EBV genome. B95-8 is a 
marmoset monkey B-lymphocyte cell line containing the 
complete EBV genome, producing complete viral 
particles. Cell cultures were grown on a growth medium 
consisting of 90% RPMI 1640 medium (Sigma, USA), 
10% solution of fetal calf serum (Sigma, USA), penicillin 
(100 μg / ml), streptomycin (100 μg / ml ), L-glutamine (2 
mM), in a thermostat at 37 ° C with the addition of 5% CO2. 
To control cell viability, a 0.4% trypan blue dye (Sigma, 
United States) was used. EBV was isolated from a 
lymphoblastoid culture of B95-8 cells (B-lymphocytes of 
monkeys-marmazetka), which produces this virus, 
according to the method of Walls, Crawford [22].  
 
Investigated substances. Albuvir (N. 1) - dynamic acylated 
acidic peptides - antagonists of signal peptides of nuclear 
(nucleolar) localization and polyribosomes. Lysine 
trisuccinamide (N. 2). Acyclovir was used as a reference 
drug (literature data) (Acycloguanosine (lot 117F0756), 
m.v. 225.2 (Sigma, USA)) (N. 2) [23]. HPLC characteristics 
of Albuvir are shown in Fig. 1. The test substances were 
dissolved in RPMI-1640 medium, filtered through 
sterilizing filters from Sarstredt, Germany, with a pore size 
of 0.22 μm. Working dilutions were prepared in growth 
medium (95% RPMI-1640 medium with 5% fetal calf 
serum).  
 
MTT test. The cytotoxic concentration was determined in 
the Raji lymphoblastoid cell system using the colorimetric 
MTT method. This method is widely used to determine the 
CC50 of potential drugs in the study of the cytopathic 
action of viruses in vitro. MTT (3, (4,5 dimethyltriazol-2-
yl) -2,5-diphenyltetrosolium bromide) was dissolved in 
sterile phosphate-buffered saline (PBS) (pH 7.4) at room 
temperature to a concentration of 5 mg / ml and filtered ( 
0.22 micron filters "Sarstredt", Germany). Special 
attention was paid to the standardization of experimental 
conditions. Raji cells were plated into 96 well culture 
plates, 100 μl per well, 25 μl MTT (final concentration 5 
μg / ml) was added and incubated for 3 h at 37 ° C in an 
atmosphere of 5% CO2. After incubation, cells were 
washed with PBS and resuspended in 96% ethanol to 
dissolve formazan. The results were analyzed 
spectrophotometrically on a Dynatech reader (Sweden) at 
a wavelength of 540 nm. 
 
Polymerase chain reaction. The degree of influence of 
drugs on EBV reproduction was determined using PCR test 
systems "AmpliSens-100-R". A fragment encoding the 
VCA protein of the virus with a size of 290 nucleotide 
sequences was the chosen genome region of the Epstein-
Barr virus. The control was cells that, after infection with 
the virus, were incubated in the growth medium without 
the addition of the substances that were studied. We 
determined the percentage of inhibition of the level of 
accumulation of viral DNA in the samples treated with the 
test substances in relation to the control sample, the value 
of which was taken as 100%. 
 
Statistical Methods. According to the obtained research 
results, statistical analysis was carried out using standard 
methods [24]. To determine the CC50 and IC50 indicators, 
we used the regression analysis method (using the 
Microsoft Excel computer program), which allows us to 
characterize the relationship between two signs, namely, 
taking as a basis one of the signs (in our case, 
concentration) to assess the variation and the other 
indicator associated with it (optical density of the 
prototype). 
 
Results and discussion 
According to the results of the MTT method, the IC50 (the 
dose of the compound that leads to inhibition of the 
viability of 50% of cells in culture) was calculated, and the 
effect on the mitochondrial and lysosomal activities of cells 
was also investigated. Directly, the decrease in 
mitochondrial and lysosomal cell activity was determined 
by comparing the values of samples exposed to the action 
of the compounds for 48 hours with the values of the 
control cells. 
The decrease in mitochondrial activity under the 
action of compound N. 1 of B95-8 cells is shown in Fig. 1. 
 
 Fig. 1. Cytotoxicity by MTT-method of compound   N. 1.  
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Concentrations correspond to table 1. 
 
As can be seen from Figure 1, a 50% drop in the 
mitochondrial activity of cells in culture is noticeable 
already in the presence of substance N. 1 at a concentration 
of 0.07 ug/mL. At high concentrations of Albuvir (N. 1), 
the activity of mitochondria in cells drops to 20%. 
The decrease in mitochondrial activity under the action of 
compound N. 2 of B95-8 cells is shown in Figure 2. 
 
Fig. 2. Cytotoxicity by the MTT method of compound N. 2 based on a decrease in mitochondrial activity. 
 Compound N. 1 turned out to be the most cytotoxic, while 
compound N. 2 turned out to be less toxic. The IC50 value 
is shown in Table 1. 
Table 1. The IC50 for researched substances 
Index ІС50, mg/mL 
Culture В95-8 
Compound №1 №2 
MTT method 0,0068 2,5 
 
Inhibition of the lysosomal system was also dose-
dependent. The toxicity was tested at the doses indicated in 
Tables 1 and 2 for the B95-8 culture. Compound N. 1 was 
almost 3 orders of magnitude more active in the MTT test 
than compound N. 2 according to IC50 
The nature of suppression of the lysosomal system of B95-
8 cells is shown in Figure 3 for compound N. 1. 
 
Fig.3. Cytotoxicity by the neutral red method for compound N. 1 and culture B95-8; concentration of compound 
N. 1 from table 2. 
 
As can be seen from Figure 4, a drop to 20% of the 
lysosomal activity of the B95-8 cell culture for compound 
N. 1 was observed at a concentration of -2 log10 m mg / 
mL, respectively, the cytotoxicity against infected EBV 
cells in the latent phase is quite noticeable in comparison 
with the control - acyclovir. The latter did not have any 
significant cytotoxic effect on latently infected cells at all. 
The inhibition of the lysosomal system by compound 2 is 
shown in Figure 4. 
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Fig.4. Cytotoxicity by the neutral red method for compound N. 2 and culture B95-8. IC50 indices by the method of 
neutral red culture B95-8 are shown in Table 2. 
 




Substance №1 №2 
NR method 0,0079 1,94 
To confirm the data obtained by the MTT and NR method for compound N. 1, the number of dead cells was counted 
using the trypan blue method. The result is shown in Figure 5. 
 
 
Fig. 5. Trypan blue cytotoxicity for compound N 1.  
 
 
It should be noted that compound N. 1 at a concentration 
of 2.1% (21 mg / ml) led to complete cell lysis, and can 
also interact with the artificial MTT substrate, staining it 
purple. 
The study of compounds for cytotoxicity for the BHK-21 
culture revealed a significantly lower toxicity of the 
compounds for this culture. 
Studies were conducted for the culture of VNK-21 in the 
concentrations given in Table 3. 
 
Table 3. Substance study onVNK-21 in the different concentrations 
Substance N 1 Substance N 2 
Dilution Concentration, 
mg/ml 
Log 10, mg/mL Dilution Concentration, 
mg/mL 
Log10, mg/mL 
1^640 0,328 -0,4841262 1^640 0,453 -0,3439018 
1^320 0,656 -0,1830962 1^320 0,906 -0,0428718 
1^160 1,3125 0,11809931 1^160 1,8125 0,25827802 
1^80 2,625 0,41912931 1^80 3,625 0,55930801 
1^40 5,25 0,7201593 1^40 7,25 0,86033801 
1^20 10,5 1,0211893 1^20 14,5 1,161368 
1^10 21 1,32221929 1^10 29 1,462398 
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Inhibition of mitochondria activity by the composition N.1 
for the culture of VNK-21 is shown in Figure 6. 
 
Fig. 6. Cytotoxicity by MTT method  for compounding N.1 and culture of VNK-21. 
 
The decrease in mitochondria activity by the composition 






Fig. 7. Cytotoxicity by MTT method for compounding N.2 and culture of VNK-21. 
 
A dose-dependent type of action of compounds on the 
mitochondrial activity of VNC-21 culture cells has been 
established, and IC50 has been calculated for this culture 
(see Table 4). 
 




Substance №1 №2 
MTT 1,06 3,5 
As for the culture of B95-8, the compound N.1 was more 
toxic than control.The ability to stimulate apoptosis by the 
composition N.1 has been tested by the staining of cells 
with the fluorescent dye Hoechst 33342, which intercalates 
in the DNA of both living and dead cells, and the 
morphological state of the nucleus can determine the 
apoptotic or necrotic state of cells, as well as its normal 
state. 
Compound number 1 was tested for the ability to stimulate 
apoptosis in 3 concentrations with exposure at 4:00 on the 
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Table 5. Effect of different concentrations of substance N. 1 (Albuvir) on the death of B95-8 culture cells 
Concentration, 
mg/mL 
Number of cells, % Counted cells total 
number 
Normal Apoptotic Necrotic 
0,0046 64 22 14 100 
0,0021 73 19 8 142 
0,00021 81 11 8 100 
Cell control 95 - 5 81 
The ability to induce apoptosis is also dose-dependent, 
with a maximum rate of 22%. 
Fig. 8-9 shows photos taken with fluorescent microscopy. 
 
Fig.8. Photographs are obtained in fluorescent microscopy, which depict normal and apoptotic cells (there is a 
defracation of the nucleus). Increase of 100, ultraviolet with blue filter. 
Fig.9. Photographs were obtained with fluorescent microscopy, which depict normal and apoptotic cells (there is 
a deframentation of the nucleus). Increase of 900 
 
Thus, the indicators of cytotoxicity N1, N2 and reference 
of the drug Acyclovir MTT-method, which includes 
colorimetric detection of living cells, have been 
determined. Using linear regression analysis, the 
indicators of IC50 were calculated, which amounted to: for 
N1 - 1.06 mg/mL, substances N2 - 3.5 mg/mL, for 
Acyclovir - 5 mg/mL. 
To determine the antiviral action of each sample 
under study, an inhibitory concentration (IC50) was 
determined, i.e. concentration, reducing reproduction of 
the virus by 50%. The drug N. 1 was studied in 
concentrations of 0.1, 0.5, 1, 5, 10 ug/mL. Each 
concentration was investigated in three repetitions. The 
drug remained in the environment throughout the study 
cycle. 
The polymerase chain reaction method was used 
to determine the level of EBV reproduction in the cells 
studied. The analysis of the antiviral action of the drugs 
was carried out after 48 hours, as this time point is optimal 
both in terms of the dynamics of the growth of the Raji cell 
line and the reproductive cycle of EBV.  
Antiviral activity has been established that the 
IC50 Albuvir (N1) is 5 ug/mL, for reference-drug 
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Table 6. The level of inhibition of reproduction of the Epstein-Barr virus under the influence of various 
concentrations of the experimental drugs by PCR method. 
Concentration of 
ug/ml 
The level of inhibition of 
reproduction of the Epstein-Barr 
virus (%) 
Albuvir Acyclovir 
0,1 20 0 
0,5 50 0 
1 56 0 
5 67 0 
10 80 10 
So, it is determined that Albuvir in the range of 
experimental concentrations has low toxicity in the culture 
of raji cells. A 50% decrease in proliferative activity is 
observed at 840 ug/mL of the substance, which 
corresponds to the value of CC50. For Acyclovir CC50 was 
5000 micrograms / ml. When observing the antiviral 
activity of the studied drugs in the culture of Raji cells, the 
effective concentration EC50, that is, the concentration that 
reduces the reproduction rate of the Epstein-Barr virus by 
50% is 1 ug/mL, for reference drug Acyclovir - 222 ug/mL. 
The Selectiveness Index (SI) was determined by the ratio 
of CC50 to the EC50. SI Albuvir was 8400 and reference-
drug Acyclovir was 22.6. Antiviral drugs that have SI 
above 16 when researching the inhibitory effects on 
reproduction of the virus in vitro systems are considered 
active and may be recommended for further animal 
research. It has been shown that Albuvir has the maximum 
antiviral activity compared to the reference drug Acyclovir 
and it may be a promising drug for the treatment of 
diseases caused by EBV. Despite the different 
development of viral infection in different diseases 
depending on the localization in the body, we considered 
it appropriate to conduct studies aimed at the interaction of 
this drug and the virus in different cell cultures. The 
Namalwa cell line, which does not contain the Epstein-
Barr virus genome, was used for research, as a line where 
the abortive replication of the virus occurs according to a 
latent scheme and a B95-8 cell culture - a cell line of B-
lymphocytes of marmoset monkeys containing the 
complete EBV genome and produces complete viral 
particles. 
According to the above methodical approaches, 
the cytotoxic and antiviral action of Albuvir in B95-8 cells 
was analyzed. It is determined that in the range of 
concentrations of 50-500 ug/mL this drug has little effect 
on the viability of cells. The concentration, which reduces 
the viability of the cellular population by 50%, is about 
1250 ug/mL. In the minimum studied concentration of 0.5 
mcg/ml, up to 20% of the inhibition of the reproduction of 
the virus is observed. Thus, the B95-8 cell culture is 
insensitive to the cytotoxic action of the Albuvir, and it is 
an active inhibitor of EBV reproduction. The index of 
selectivity in this system for Albuvir was 500 as a result of 
the determination of its anti-EBV activity in the culture of 
cells Namalwa by PCR method found that the 
concentration of 50 ug/mL reduces the level of 
accumulation of EBV DNA by 50%. Based on its 
cytotoxic concentration in this cell culture, which is 3000 
ug/mL, the selective index is 60. In this culture of cells 
anti-EBV activity is moderate. 
In the table. 7 is induced by the CC50, EC50 ta SI 
for Albuvir in the cell cultures B95-8 and Namalwa. 
 
 





СС50 1250 ug/ mL 3000 ug/mL 
ЕС50 2,5 ug/ mL 50 ug/ mL 
IS 500 60 
 
Few thoughts about future drug development. The cost of 
developing new drugs grow, and the return on investment 
for drug development is decreasing every year. At the same 
time, expenses on research and development (R&D) are 
gradually increasing each year. The development of drugs 
is more time-consuming, while being more expensive, 
despite recent technological improvements. New 
technological advancements led to more precision in 
quantitative and qualitative control of drug research.  This 
trend has been observed from the 50s to the present, and 
the cost of developing a new drug has doubled 
approximately every ten years.                                                                  
According to Genrich Altshuller [25], the life of a 
technological system (as incidentally in other systems, 
including biological) can be presented in the shape of an 
S-curve, showing how the main characteristics of a system 
change in time. In different systems this curve naturally 
has its own individual features but it always has 
characteristic segments, which are brought out 
schematically with crudely depicted emphasis. In 
"childhood " the system develops slowly. Then the time of 
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"growing up" and "maturity» comes - the system is quickly 
improved, and its mass application begins. At some point 
the rates of development start to fall and "old age" sets in. 
Later two variants. One system either degrades, changing 
into another, a system that is different in its principle, or 
for a long time stick to achieved values. Based on TRIZ, 
we could think about some future evolution of medicine 
and pharmaceuticals to Drugs dynamization as a future 
pharmaceutical industry – this are drugs with elements of 
a living organism, meaning it is capable of adapting to the 
disease mutations and the body of a particular person, 
without or with very minimal side effects.   
 
Conclusion 
Effect of the dynamic antiviral drug Albuvir on 
reproduction and apoptosis latently infected with the 
Epstein-Barr virus cells in vitro. Modern approaches to the 
treatment of herpes infection, in particular the Epstein-Barr 
virus (EBV), include the use of ethyotropic drugs, as well 
as sensitizing therapy. This virus plays an important role in 
the etiology of nasopharyngeal carcinoma, stomach 
carcinoma, Burkitt lymphoma and lymphoproliferative 
syndromes. The range of drugs active against EBV remains 
very limited to ganciclovir and acyclovir. The search for 
new compounds active against EBV remains relevant. The 
aim of this study was to find out the anti-EBV activity of 
the drug Albuvir in Raji, B95-8, Namalwa lymphoblastoid 
cells. The cytotoxicity concentration (CC50) was 
determined, which was 3000 ug/mL, and the concentration 
of the drug that inhibits the reproduction of the virus (EC50) 
was 0.1 ug/mL. The ability of the drug Albuvir to inhibit 
the reproduction of the Epstein-Barr virus in all studied cell 
cultures was revealed. When the economic efficiency of 
creating static drugs in accordance with the S-shaped curve 
decreases, the need arises for a transition to a supersystem, 
namely, the creation of dynamic drugs systems. 
It has been proven that the drug Albuvir is able to 
inhibit the reproduction of the Epstein-Barr virus in Raji, 
B95-8 and Namalwa cell cultures. It is determined that the 
drug has a high activity in the culture of Raji cells (SI 
8400), respectively, the drug is promising enough to 
develop as a treatment for EBV-associated diseases. 
 
Acknowledgments 
We are grateful to the  Ph.D., Svetlana Zagorodnaya, head 
of the virus reproduction department of the Microbiology 
and Virology of the D.K. Zabolotny Institute of 
Microbiology and Virology National Academy of Sciences 
of Ukraine for providing assistance in conducting 
virological studies of the developed drug. 
 
Conflict of Interests 
No conflict of interests   
 
Reproduction and apoptosis of EBV- latent infected 
cells under influence a TRIZ-created antiviral drugs 
Farber B, Martynov A, Klein I. 
Introduction. We had worked persistently and in 1997, 
the first model of such a structure based on oligopeptides 
of horse albumin was revealed. We named this project 
and called Albuvir (combined from the word Albumin 
and the word virus) and applied in veterinary medicine, 
where viral infections represent more than 95% of all 
pathologies. In 2000 an application was filed for the first 
modification of this drug. Subsequently, for the 
production and sale of this product, registration 
certificates of the State Committees in Veterinary 
Medicine of Eastern European countries were obtained.  
In 2010, we signed a license agreement to transfer of 
limited rights in the field of veterinary medicine for the 
production and sale of Albuvir in Eastern Europe. The 
drug was produced commercially and was successfully 
used to cure hundreds of thousands of chickens, rabbits, 
sheeps, cows, pigs, pigeons, fish (industrial - sturgeon), 
cats, dogs, geese, ducks, and other types of farm birds 
and animals. Thus, the task of this work was to study the 
ability of Albuvir to inhibit EBV reproduction and induce 
apoptosis of latently infected cells in the culture. 
Materials and methods. Cell culture. The inhibitory 
effect of Albuvir on EBV was studied in the following 
cell cultures: Raji - cell culture of the B-phenotype of 
Burkitt's lymphoma. Namalwa is a B-phenotype cell 
culture from Burkitt's lymphoma that lacks the EBV 
genome. B95-8 is a marmoset monkey B-lymphocyte cell 
line containing the complete EBV genome, producing 
complete viral particles. To control cell viability, a 0.4% 
trypan blue dye (Sigma, United States) was used. EBV 
was isolated from a lymphoblastoid culture of B95-8 cells 
(B-lymphocytes of monkeys-marmazetka), which 
produces this virus, according to the method of Walls, 
Crawford. Investigated substances. Albuvir (N. 1) - 
dynamic acylated acidic peptides - antagonists of signal 
peptides of nuclear (nucleolar) localization and 
polyribosomes. Lysine tris-succinamide (N. 2). Acyclovir 
was used as a reference drug (references data)  MTT test. 
The cytotoxic concentration was determined in the Raji 
lymphoblastoid cell system using the colorimetric MTT 
method. This method is widely used to determine the 
CC50 of potential drugs in the study of the cytopathic 
action of viruses in vitro. Raji cells were plated into 96 
well culture plates, 100 μl per well, 25 μl MTT (final 
concentration 5 μg / ml) was added and incubated for 3 h 
at 37 ° C in an atmosphere of 5% CO2. After incubation, 
cells were washed with PBS and resuspended in 96% 
ethanol to dissolve formazan. The results were analyzed 
spectrophotometrically on a Dynatech reader (Sweden) at 
a wavelength of 540 nm. Polymerase chain reaction. The 
degree of influence of drugs on EBV reproduction was 
determined using PCR test systems "AmpliSens-100-R". 
A fragment encoding the VCA protein of the virus with a 
size of 290 nucleotide sequences was the chosen genome 
region of the Epstein-Barr virus. The control was cells 
that, after infection with the virus, were incubated in the 
growth medium without the addition of the substances 
that were studied. We determined the percentage of 
inhibition of the level of accumulation of viral DNA in 
the samples treated with the test substances in relation to 
the control sample, the value of which was taken as 
100%. Results and discussion. Effect of the dynamic 
antiviral drug Albuvir on reproduction and apoptosis 
latently infected with the Epstein-Barr virus cells in vitro. 
Modern approaches to the treatment of herpes infection, 
in particular the Epstein-Barr virus (EBV), include the 
use of ethyotropic drugs, as well as sensitizing therapy. 
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The range of drugs active against EBV remains very 
limited to ganciclovir and acyclovir. The search for new 
compounds active against EBV remains relevant. The 
aim of this study was to find out the anti-EBV activity of 
the drug Albuvir in Raji, B95-8, Namalwa 
lymphoblastoid cells. The cytotoxicity index (CC50) was 
determined, which was 3000 ug/mL, and the 
concentration of the drug that inhibits the reproduction of 
the virus (EC50) was 0.1 ug/mL. The ability of the drug 
Albuvir to inhibit the reproduction of the Epstein-Barr 
virus in all studied cell cultures was revealed. When the 
economic efficiency of creating static drugs in 
accordance with the S-shaped curve decreases, the need 
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arises for a transition to a supersystem, namely, the 
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